01:49 PM EDT, 09/17/2024 (MT Newswires) -- Novartis ( NVS ) said Tuesday that the US Food and Drug Administration has approved Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative stage II and III early breast cancer at high risk of recurrence.

The approval is based on results from the phase three Natalee study that showed Kisqali reduced the risk of disease recurrence in the indicated patient group, according to the company.

Novartis ( NVS ) developed Kisqali in research collaboration with Astex Pharmaceuticals.

Price: 115.53, Change: -1.43, Percent Change: -1.22